{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:19:54Z","timestamp":1788358794900,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd010533.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000}}],"reference-count":279,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010533.pub3","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:26:10Z","timestamp":1743215170000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma"],"prefix":"10.1002","volume":"2025","author":[{"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Cochrane Evidence Synthesis Unit (CESU) Germany\/UK, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Goldkuhle","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Cochrane Evidence Synthesis Unit (CESU) Germany\/UK, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Department of Hematology and Stem Cell Transplantation; West German Cancer Center, University Hospital Essen, University of Duisburg-Essen; Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[{"name":"Department for Nuclear Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Sickinger","sequence":"additional","affiliation":[{"name":"Clinical Department of Pediatrics and Adolescent Medicine; University Hospital St. P\u00f6lten; Sankt P\u00f6lten Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Cochrane Evidence Synthesis Unit (CESU) Germany\/UK, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Cochrane Evidence Synthesis Unit (CESU) Germany\/UK, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"Suppl 2","key":"10.1002\/14651858.CD010533.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/HS9.0000000000000060","article-title":"Final analysis of the AHL2011 randomized phase III LYSA study comparing an early pet driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma","volume":"2","author":"Casasnovas","year":"2018","journal-title":"HemaSphere"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2018.36.15-suppl.7503","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study","volume":"36","author":"Casasnovas","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD010533.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 LYSA study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0004|cit4","first-page":"4","article-title":"Baseline total metabolic volume (TMTV) predicts the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial","volume":"101","author":"Casasnovas","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography-driven strategy in advanced Hodgkin Lymphoma: prolonged follow-up of the AHL2011 phase III Lymphoma Study Association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2016.34.15_suppl.7509","article-title":"Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial","volume":"34","author":"Casasnovas","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"TPS8615","DOI":"10.1200\/jco.2013.31.15_suppl.tps8615","article-title":"AHL 2011: a Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma","volume":"31","author":"Casasnovas","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-136056","article-title":"PET-guided strategy improves the safety of BEACOPP-based treatment in advanced Hodgkin lymphoma: prolonged follow-up of the LYSA AHL 2011 phase 3 study","volume":"136","author":"Casasnovas","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers15010053","article-title":"Influence of sociodemographic determinants on the Hodgkin lymphoma baseline characteristics in long survivors patients enrolled in the prospective phase 3 trial AHL2011","volume":"15","author":"Chevreux","year":"2022","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/humrep\/35.Supplement_1.1","article-title":"Ovarian function recovery in newly diagnosed advanced Hodgkin lymphoma patients treated with PET-adapted regimen: prospective analysis of a multicentric randomized phase 3 trial (AHL2011)","volume":"35","author":"Demeestere","year":"2020","journal-title":"Human Reproduction (Oxford, England)"},{"issue":"29","key":"10.1002\/14651858.CD010533.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1200\/JCO.21.00068","article-title":"Gonadal function recovery in patients with advanced Hodgkin Lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011)","volume":"39","author":"Demeestere","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/blood-2021-147177","article-title":"Total metabolic tumor volume and tumor dissemination are independent prognostic factors in advanced Hodgkin lymphoma","volume":"138 Suppl 1","author":"Kanoun","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0014|cit14","first-page":"S125","article-title":"Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL): ancillary study of AHL2011 LYSA trial","volume":"43 Suppl 1","author":"Kanoun","year":"2016","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2019-125976","article-title":"Stage IIb high risk Hodgkin Lymphoma treated in the H10 and AHL2011 trials: similar efficacy of both strategies and prognostic impact of baseline TMTV and PET2 response","volume":"134 Suppl 1","author":"Rossi","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD010533.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1182\/blood.V128.22.1825.1825","article-title":"The combination of high expression of CD68-positive tumor-associated macrophages and PET2-positivity predicts unfavorable outcome in patients with classical Hodgkin lymphoma treated in the LYSA AHL2011 study","volume":"128","author":"Traverse-Glehen","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.166_2631","article-title":"Preliminary results of a quality control study on involved node radiotherapy in the EORTC\/LYSA\/FIL H10 trial on stages I\/II Hodgkin lymphoma","volume":"37 Suppl 2","author":"Aleman","year":"2019","journal-title":"Hematological Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010533.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD010533.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood.V114.22.97.97","article-title":"First report on the H10 EORTC\/GELA\/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I\/II Hodgkin's lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL)","volume":"114","author":"Andre","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V120.21.549.549","article-title":"Interim analysis of the randomized EORTC\/LYSA\/FIl Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I\/II Hodgkin lymphoma","volume":"120","author":"Andre","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0022|cit22","unstructured":"Andre MP An update on the EORTC\/LYSA\/FIL H10 trial 9th International Symposium on Hodgkin Lymphoma Cologne, 2013, Germany"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1007\/s00259-018-4148-3","article-title":"Deauville score evaluation of PET2 positive patients included in the H10 trial","volume":"45 Suppl 1","author":"Cottereau","year":"2018","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hon.2437_16","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV) for patients with early stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC\/LYSA\/FIL) trial","volume":"35 Suppl 2","author":"Cottereau","year":"2017","journal-title":"Hematological Oncology"},{"issue":"13","key":"10.1002\/14651858.CD010533.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD010533.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood.V128.22.184.184","article-title":"Prognostic value of baseline quantitative PET metrics for patients with unfavourable early stage Hodgkin lymphoma enrolled in the standard arm of the EORTC\/Lysa\/FIL H10 Trial","volume":"128","author":"Cottereau","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.3324\/%25x","article-title":"Contribution of PET \/CT in the design of the involved node radiotherapy (INRT) concept for patients with localized Hodgkin lymphoma: preliminary results on 117 patients entered in the H10 trial","volume":"95 Suppl 4","author":"Edeline","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy - a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1359-6349(09)70541-5","article-title":"Single institution preliminary experience on dose reduction to organs at risk in thoracic radiotherapy for patients enrolled in EORTC-GELA-IIL H10 study protocol on early stage Hodgkin's Lymphoma","volume":"7 Suppl","author":"Filippi","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/hon.104_2630","article-title":"Outcome and treatment of relapsing early PET negative patients included in the EORTC\/LYSA\/FIL H10 trial on stages I\/II Hodgkin lymphoma","volume":"37 Suppl 2","author":"Gac","year":"2019","journal-title":"Hematological Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","author":"Girinsky","year":"2014","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/%25x","article-title":"Comparison of visual and quantitative assessment for FDG-PET interpretation in Hodgkin lymphoma after 2 cycles of ABVD. The EORTC-GELA-IIL H10 trial experience","volume":"95 Suppl 4","author":"Jullian","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hon.2880","article-title":"Baseline maximum tumour diameter is associated with event-free survival for PET-negative patients with limited-stage Hodgkin lymphoma: analysis of the H10 and rapid trials","volume":"39 Suppl 2","author":"Phillips","year":"2021","journal-title":"Hematological Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/%25x","article-title":"Positive interim PET after 2 ABVD is more frequent in patients with unfavourable stage I\/II Hodgkin lymphoma and bulky mediastinum than in non-bulky. The EORTC-GELA-IIL H10 trial experience","volume":"95 Suppl 4","author":"Yeddes","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s40336-017-0227-x","article-title":"Diagnostic accuracy of FDG PET\/CT at the of treatment of Hodgkin lymphoma in the HD0607 trial","volume":"5 Suppl 1","author":"Biggi","year":"2017","journal-title":"Clinical and Translational Imaging"},{"issue":"3","key":"10.1002\/14651858.CD010533.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hon.3117","article-title":"Predictive value on advanced Hodgkin lymphoma treatment outcome of end-of treatment FDG PET\/CT in the HD0607 clinical trial","volume":"41","author":"Biggi","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00259-011-1908-8","article-title":"Concordance between six Italian centres of PET reporting criteria in the prospective clinical trial HD 0607 in advanced-stage Hodgkin Lymphoma","volume":"38 Suppl 2","author":"Biggi","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s40336-019-00318-3","article-title":"Diagnostic accuracy of FDG PET\/CT at the end of treatment of Hodgkin lymphoma in the HD0607 trial","volume":"7 Suppl 1","author":"Buschiazzo","year":"2019","journal-title":"Clinical and Translational Imaging"},{"issue":"21","key":"10.1002\/14651858.CD010533.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1182\/blood.V116.21.3891.3891","article-title":"Interim-PET scan interpretation in the ongoing prospective clinical trial HD 0607, in advanced-stage Hodgkin lymphoma: results of the expert panel review","volume":"116","author":"Gallamini","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hon.2879","article-title":"Baseline metabolic tumor volume and IPS predict ABVD failure in advanced-stage Hodgkin lymphoma with a negative interim PET scan after 2 chemotherapy cycles. A retrospective analysis from the GITIL\/FIL HD0607 trial","volume":"39 Suppl 2","author":"Gallamini","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2021-152292","article-title":"Lesion dissemination in baseline PET\/CT (D-MAX) and IPS score predict ABVD treatment outcome in PET-2 negative advanced-stage Hodgkin lymphoma patients enrolled in the prospective GITIL\/FIL HD0607 trial","volume":"138 Suppl 1","author":"Gallamini","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/%25x","article-title":"Early treatment intensification in advanced-stage high-risk Hodgkin Lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses - second interim analysis of the GITIL\/FIL HD0607 clinical trial","volume":"98 Suppl 2","author":"Gallamini","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD010533.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood.V120.21.550.550","article-title":"Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL\/FIL HD0607 clinical trial","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/hon.2227","article-title":"Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL\/FIL DH0607 trial","volume":"33","author":"Gallamini","year":"2015","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/hon.105_2629","article-title":"Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD. Final analysis of the randomized HD0607 trial","volume":"37 Suppl 2","author":"Gallamini","year":"2019","journal-title":"Hematological Oncology"},{"issue":"33","key":"10.1002\/14651858.CD010533.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3324\/%25x","article-title":"Early chemotherapy intensification with escalated BEACOPP in advanced-stage Hodgkin lymphoma with a positive interim PET-CT after 2 ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"102 Suppl 2","author":"Gallamini","year":"2017","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/annonc\/mdr212","article-title":"Multicentre clinical study with early treatment intensification in high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses - GITIL HD0607 study","volume":"22 Suppl 4","author":"Gallamini","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010533.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/biomedicines9080971","article-title":"Myocardial metabolic response predicts chemotherapy curative potential on Hodgkin Lymphoma: a proof-of-concept study","volume":"9","author":"Marini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2018-99-115346","article-title":"Prognostic relevance of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) in newly diagnosed advanced-stage Hodgkin lymphoma patients treated up-front with a PET-2 risk adapted protocol","volume":"132 Suppl 1","author":"Romano","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD010533.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1002\/cam4.3396","article-title":"The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: a subanalysis of the prospective phase II PET-2-adapted HD0607 trial","volume":"9","author":"Romano","year":"2020","journal-title":"Cancer Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1182\/blood.V130.Suppl_1.1511.1511","article-title":"Early reduction of serum TARC levels predicts prognosis of patients treated with a pet-adapted strategy for advanced stage Hodgkin lymphoma (HL) in the GITIL\/FIL HD0607 trial","volume":"130 Suppl 1","author":"Viviani","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/hon.2775","article-title":"Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy","volume":"38","author":"Viviani","year":"2020","journal-title":"Hematological Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-019-03893-7","article-title":"The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of PET-guided treatments","volume":"99","author":"Bari","year":"2020","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1016\/S0167-8140%2819%2930922-3","article-title":"Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial","volume":"133 Suppl 1","author":"Ricardi","year":"2019","journal-title":"Radiotherapy and Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010533.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Advances"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00277-019-03889-3","article-title":"Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study","volume":"99","author":"Rigacci","year":"2020","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/hon.2437","article-title":"Clinical characteristics of patients with negative interim-pet and positive final PET: data from the prospective PET-oriented HD0801 study by Fondazione Italiana linfomi (FIL)","volume":"35 Suppl 2","author":"Rigacci","year":"2017","journal-title":"Hematological Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2019.06.445","article-title":"Consolidating involved field radiotherapy prevents early and local recurrences in early stage Hodgkin Lymphoma","volume":"105 Suppl 1","author":"Baues","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ijrobp.2021.07.1697","article-title":"Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin Lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial","volume":"111","author":"Baues","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2019.06.380","article-title":"PET-guided treatment of early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase 3 trial HD16 by the GHSG","volume":"105 Suppl 1","author":"Eich","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood.2023019939","article-title":"Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies","volume":"142","author":"Eichenauer","year":"2023","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890648.99383.b7","article-title":"Interim PET-guided treatment of early-stage nodular lymphocyte-Ppredominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies","volume":"6 Suppl 5","author":"Eichenauer","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2021-145427","article-title":"Treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD16 study","volume":"138 Suppl 1","author":"Eichenauer","year":"2021","journal-title":"Blood"},{"issue":"31","key":"10.1002\/14651858.CD010533.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0070|cit70","first-page":"297","article-title":"PET positivity after 2 cycles of ABVD is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study","volume":"42","author":"Fuchs","year":"2019","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0071|cit71","first-page":"16","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"16","author":"Fuchs","year":"2023","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2021-152260","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin Lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"138 Suppl 1","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0073|cit73","first-page":"167","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"45","author":"Jacob","year":"2022","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"A39","DOI":"10.1055\/s-007-36540","article-title":"Recruitment and PET interpretation in the HD16 trial for early stage Hodgkin lymphoma. Treatment stratification by FDG-PET","volume":"51 (2)","author":"Kobe","year":"2012","journal-title":"Nuklearmedizin [Nuclear Medicine]"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-0042-1745979","article-title":"Role of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"61","author":"Van Heek","year":"2022","journal-title":"Nuklearmedizin [Nuclear Medicine]"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890664.81647.d7","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"6","author":"Van Heek","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"Van Heek","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HS9.0000000000000404","article-title":"Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized phase III HD17 trial by the GHSG","volume":"4","author":"Borchmann","year":"2020","journal-title":"HemaSphere"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood.2023019939","article-title":"Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies","volume":"142","author":"Eichenauer","year":"2023","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890648.99383.b7","article-title":"Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies","volume":"6 Suppl 5","author":"Eichenauer","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.HS9.0000547879.40964.5c","article-title":"Quality assurance of involved-node radiotherapy: first results of the HD17-trial of the GHSG","volume":"2 Suppl 3","author":"Kriz","year":"2018","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1183906","DOI":"10.3389\/fonc.2023","article-title":"Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial","volume":"13","author":"Oertel","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.HS9.0000890936.73031.da","article-title":"Estimating the dosimetric benefit of involved node radiotherapy in comparison to involved field radiotherapy - implications from the GHSG HD17 trial","volume":"6 suppl 5","author":"Oertel","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0085|cit85","first-page":"42","article-title":"From involved-field to involved-node - quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group","volume":"6 Suppl 5","author":"Oertel","year":"2022","journal-title":"HemaSphere"},{"issue":"3","key":"10.1002\/14651858.CD010533.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","article-title":"Radiation therapy in the German Hodgkin Study Group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2023","journal-title":"Advances in Radiation Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/ejh.14093","article-title":"Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: data from the phase III HD17 trial","volume":"111","author":"Van Heek","year":"2023","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2437","article-title":"Ebeacopp with or without rituximab in interim-PET-positive advanced-stage Hodgkin lymphoma: updated results of the international, randomized phase 3 GHSG HD18 trial","volume":"35 Suppl 2","author":"Borchmann","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3324\/%25x","article-title":"Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international, randomized phase 3 trial HD18 by the German Hodgkin Study Group","volume":"102 Suppl 2","author":"Borchmann","year":"2017","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood.V130.Suppl_1.737.737","article-title":"Early interim PET in patients with advanced-stage Hodgkin's lymphoma treated within the phase 3 GHSG HD18 study","volume":"130 Suppl 1","author":"Borchmann","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood.V124.21.500.500","article-title":"Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study","volume":"124 (21)","author":"Borchmann","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/bjh.17770","article-title":"Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group","volume":"196","author":"Eichenauer","year":"2021","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.annonc.2021.02.018","article-title":"PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study","volume":"32","author":"Eichenauer","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/HS9.0000000000000404","article-title":"PET-2-guided escalated BAECOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"4 Suppl 1","author":"Eichenauer","year":"2020","journal-title":"HemaSphere"},{"issue":"22","key":"10.1002\/14651858.CD010533.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00259-023-06431-w","article-title":"Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group","volume":"51","author":"Ferdinandus","year":"2023","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"21","key":"10.1002\/14651858.CD010533.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-017-3822-1","article-title":"Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim FDG-PET: final results of the international, randomized, phase 3 HD18 trial by the German Hodgkin Study Group","volume":"44 Suppl 2","author":"Kobe","year":"2017","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000479566","article-title":"Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup","volume":"40 Suppl 3","author":"Kreissl","year":"2017","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/HS9.0000000000000404","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin lymphoma: follow-up analysis of PET-2-negative patients in the HD18 trial by the German Hodgkin Study Group","volume":"4 Suppl 1","author":"Kreissl","year":"2020","journal-title":"HemaSphere"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bjh.17997","article-title":"Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma","volume":"197","author":"Kreissl","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"207-11","DOI":"10.2967\/jnumed.118.210047","article-title":"Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma","volume":"60","author":"Mettler","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.HS9.0000890600.53871.dd","article-title":"Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma","volume":"6 Suppl 5","author":"Voltin","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood-2018-99-112008","article-title":"A critical role for intratumoral and circulating LAG3 in classical Hodgkin lymphoma: analysis from the RATHL prospective phase III international clinical trial","volume":"132 Suppl 1","author":"Abro","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-011-1908-8","article-title":"Standardised PET-CT reporting for an international multicentre trial in lymphoma (RATHL)","volume":"2","author":"Barrington","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/hon.2057","article-title":"PET-CT for staging and early response - results from the response adapted therapy in advanced Hodgkin lymphoma (RATHL) study","volume":"1","author":"Barrington","year":"2013","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hon.2437","article-title":"Application of a gene expression-based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL study (CRUK\/07\/033)","volume":"35 Suppl 2","author":"Burton","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2227","article-title":"Pulmonary function and grade 3\/4 clinical events in PET negative patients taking part in the international RATHL trial (CRUK\/07\/033): a comparison of 12 vs 4 doses of bleomycin","volume":"33 Suppl 1","author":"Hague","year":"2015","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3324\/%25x","article-title":"Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: initial results. From the international RATHL study","volume":"2","author":"Johnson","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hon.2057","article-title":"Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study","volume":"31 Suppl 1","author":"Johnson","year":"2013","journal-title":"Hematological Oncology"},{"issue":"25","key":"10.1002\/14651858.CD010533.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/hon.2227","article-title":"Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK\/07\/033)","volume":"33 Suppl 1","author":"Johnson","year":"2015","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/hon.103_2630","article-title":"Transcriptional networks associated with treatment failure in advanced-stage Hodgkin lymphoma: data from the RATHL trial (CRUK\/07\/033)","volume":"37 Suppl 2","author":"Lim","year":"2019","journal-title":"Hematological Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hon.2437_18","article-title":"Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK\/07\/033)","volume":"35 Suppl 2","author":"Pike","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1078155217729776","article-title":"Outcomes of treatment for obese patients with advanced Hodgkin lymphoma in the RATHL Trial (CRUK\/07\/033)","volume":"23 Suppl 8","author":"Preston","year":"2017","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2437","article-title":"Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK\/07\/033)","volume":"35 Suppl 2","author":"Trotman","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.2879","article-title":"Relapses in interim PET negative limited-stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy - analysis of EORTC\/FIL\/LYSA H10 and UK NCRI rapid trials","volume":"39 Suppl 2","author":"Aurer","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.15226","article-title":"Treatment escalation in patients with early stage Hodgkin lymphoma and a positive pet scan after initial chemotherapy is not always required: subsidiary analysis of the UK NCRI rapid study","volume":"181 Suppl 1","author":"Barrington","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"20","key":"10.1002\/14651858.CD010533.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study","volume":"37","author":"Barrington","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hon.2227","article-title":"Cardiac radiation dose and predicted cardiac mortality in the UK NCRI rapid trial in early stage Hodgkin lymphoma","volume":"33","author":"Cutter","year":"2015","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.HS9.0000547877.95222.2e","article-title":"Cardiovascular radiation dosimetry and predicted cardiovascular risks from involved field radiotherapy within the UK 'RAPID' trial in early low-risk Hodgkin lymphoma","volume":"2 Suppl 1","author":"Cutter","year":"2018","journal-title":"HemaSphere"},{"issue":"32","key":"10.1002\/14651858.CD010533.pub3-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.21.00408","article-title":"Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of Positron Emission Tomography-directed therapy for early-stage Hodgkin Lymphoma","volume":"39","author":"Cutter","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy - a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0130|cit130","first-page":"140","article-title":"Quantitative assessment of interim PET in Hodgkin lymphoma - an evaluation of the qPET method in adult patients in the RAPID trial","volume":"60 Suppl 1","author":"Georgi","year":"2019","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"e0231027","DOI":"10.1371\/journal.pone.0231027","article-title":"Quantitative assessment of interim PET in Hodgkin lymphoma: an evaluation of the qPET method in adult patients in the RAPID trial","volume":"15","author":"Georgi","year":"2020","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.HS9.0000547870.79974.6d","article-title":"Maximum tumour dimension at baseline is associated with event-free survival in pet negative patients with stage IA\/IIA Hodgkin lymphoma in the UK NCRI rapid trial","volume":"2 Suppl 3","author":"Illidge","year":"2018","journal-title":"HemaSphere"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-136318","article-title":"Enhanced outcome prediction in early stage classical Hodgkin Lymphoma using pre-treatment biomarkers and interim PET (BioPET); a sub-analysis of the UK NCRI RAPID trial","volume":"136 Suppl 1","author":"Linton","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hon.2880","article-title":"Baseline maximum tumour diameter is associated with event-free survival for PET-negative patients with limited-stage Hodgkin lymphoma: analysis of the H10 and rapid trials","volume":"39 Suppl 2","author":"Phillips","year":"2021","journal-title":"Haematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood.V120.21.547.547","article-title":"Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial","volume":"120 (21)","author":"Radford","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3324\/%25x","article-title":"Prognostic performance of pre-treatment EORTC, GHSG and IPI risk factors and post-chemotherapy PET response in the UK NCRI RAPID trial in early stage Hodgkin Lymphoma (HL)","volume":"98 Suppl 2","author":"Radford","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/hon.2227","article-title":"PET score following 3 cycles ABVD has greater prognostic value than pre-treatment risk stratification in the rapid trial in early stage Hodgkin lymphoma (HL)","volume":"33 Suppl 1","author":"Radford","year":"2015","journal-title":"Hematological Oncology"},{"issue":"17","key":"10.1002\/14651858.CD010533.pub3-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood.V112.11.369.369","article-title":"Results of the 2nd planned interim analysis of the Rapid trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1a and 2a Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD","volume":"112 (11)","author":"Radford","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3324\/%25x","article-title":"Results of the 3rd planned interim analysis of the UK NCRI Rapid trial (involved field radiotherapy versus no further treatment) in patients with clinical stages IA\/IIA Hodgkin lymphoma and a 'negative' 18 FDG-PET scan after 3 cycles ABVD","volume":"95 Suppl 4","author":"Radford","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0142|cit142","first-page":"32","article-title":"Interim results of a UK NCRI randomized trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative pet scan in clinical stages IA\/IIA Hodgkin lymphoma","volume":"92","author":"Radford","year":"2007","journal-title":"Haematologica"},{"issue":"32","key":"10.1002\/14651858.CD010533.pub3-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0144|cit144","unstructured":"Chemotherapy with or without additional chemotherapy and\/or radiation therapy in treating children with newly diagnosed Hodgkin's disease https:\/\/clinicaltrials.gov\/study\/NCT00025259"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0145|cit145","unstructured":"Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma https:\/\/clinicaltrials.gov\/study\/NCT01132807"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0146|cit146","first-page":"13","article-title":"Results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on pet for non-bulky stage I and II Hodgkin lymphoma (CALGB\/Alliance 50604)","volume":"101 Suppl 5","author":"Straus","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB\/alliance 50604)","volume":"126 (23)","author":"Straus","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron Emission Tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0150|cit150","unstructured":"Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma https:\/\/ClinicalTrials.gov\/show\/NCT01118026"},{"issue":"16","key":"10.1002\/14651858.CD010533.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2022.40.16_suppl.7503","article-title":"First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical Hodgkin lymphoma: an updated analysis of ECHELON-1","volume":"40","author":"Ansell","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"TPS8613","DOI":"10.1200\/jco.2014.32.15_suppl.tps8613","article-title":"Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study","volume":"32","author":"Ansell","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1182\/blood-2019-124116","article-title":"Brentuximab Vedotin with chemotherapy for stage 3\/4 classical Hodgkin lymphoma (cHL): 4-Year update of the Echelon-1 study","volume":"134 Suppl 1","author":"Bartlett","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood.V130.Suppl_1.6.6","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 Echelon-1 study","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/hon.2879","article-title":"Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAS) with stage III or IV Hodgkin lymphoma: a subgroup analysis from the phase 3 ECHELON-1 study","volume":"39 Suppl 2","author":"Crosswell","year":"2021","journal-title":"Hematological Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1200\/JCO.2021.39.15_suppl.7528","article-title":"Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: a subgroup analysis from the phase 3 Echelon-1 study","volume":"39","author":"Crosswell","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u2265 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: detailed study analysis from the phase III ECHELON-1 study","volume":"107 (5)","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2019-122969","article-title":"Brentuximab Vedotin in combination with nivolumab, doxorubucin, and dacarbazine in newly diagnosed patients with advanced stage Hodgkin lymphoma","volume":"134 Suppl 1","author":"Friedman","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/HS9.0000000000000060","article-title":"Frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression-free survival vs chemotherapy alone in patients with stage III or IV Hodgkin lymphoma: phase 3 Echelon-1 study","volume":"2 Suppl 2","author":"Gallamini","year":"2018","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/HS9.0000000000000566","article-title":"Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAS) with stage iii or iv Hodgkin lymphoma: a subgroup analysis from the phase 3 Echelon-1 study","volume":"5 Suppl 2","author":"Grigg","year":"2021","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/01.HS9.0000852292.38263.b8","article-title":"Improved overall survival with first-line brentimab vedotin plus chemotherapy in patients with stage III\/IV classical Hodgkin lymphoma: 6-year analysis of ECHELON-1","volume":"6","author":"Hutchings","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/HS9.0000000000000566","article-title":"Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III or IV classical Hodgkin Lymphoma: a 5-year update of the phase 3 Echelon-1 study (NCT01712490)","volume":"5 Suppl 2","author":"Hutchings","year":"2021","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S2152-2650%2822%2901482-3","article-title":"An oncology simulation model to estimate 10-year overall survival, progression-free survival and stem cell transplantation for frontline, stage III or IV classical Hodgkin lymphoma based on overall survival update of the ECHELON-1 trial: a United States perspective","volume":"22 Suppl 2","author":"Phillips","year":"2022","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/10428194.2023.2193854","article-title":"Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial","volume":"64","author":"Phillips","year":"2023","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood-2021-147308","article-title":"An oncology simulation model to estimate 10-year progression-free survival and stem cell transplantation for frontline, stage III or IV classical Hodgkin lymphoma based on the 5-year update of the ECHELON-1 trial: a United States perspective","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/HS9.0000000000000404","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study","volume":"4 Suppl 1","author":"Picardi","year":"2020","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.16638","article-title":"Brentuximab vedotin plus chemotherapy for stage III\/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study","volume":"189 Suppl 1","author":"Radford","year":"2020","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"145-7","DOI":"10.1111\/bjh.17492","article-title":"Brentuximab vedotin plus chemotherapy for patients with previously untreated, stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)","volume":"193 Suppl 1","author":"Radford","year":"2021","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S2152-2650(21)01849-8","article-title":"HL-147: brentuximab vedotin with chemotherapy for patients with previously untreated stage III\/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study","volume":"21","author":"Ramchandren","year":"2021","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-138996","article-title":"Brentuximab vedotin with chemotherapy in frontline treatment of classic Hodgkin lymphoma nodular sclerosis syncytial variant","volume":"136 Suppl 1","author":"Steiner","year":"2020","journal-title":"Blood"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD010533.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1200\/JCO.2019.37.15_suppl.7532","article-title":"Brentuximab vedotin with chemotherapy for stage 3\/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study","volume":"37","author":"Straus","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-137089","article-title":"Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III\/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study","volume":"136 Suppl 1","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.HS9.0000547933.40071.ae","article-title":"Serum sCD30 and Tarc do not correlate with pet-based response assessment in patients (PTS) with stage III or IV classical Hodgkin lymphoma (CHL): Phase 3 ECHELON-1 study of brentuximab vedotin plus chemotherapy vs chemotherapy alone","volume":"2 Suppl 3","author":"Sureda","year":"2018","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.HS9.0000890572.92604.2c","article-title":"FDG-PET and serum Tarc levels after one cycle of Bv-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial","volume":"6 Suppl 5","author":"Diepstra","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0177|cit177","unstructured":"Very early PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single -arm phase II study https:\/\/clinicaltrials.gov\/study\/NCT03517137"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0178|cit178","unstructured":"A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant \u2018dose-dense\/dose-intense ABVD\u2019 (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002509-21\/IT"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0179|cit179","unstructured":"FIL study on ABVD DD-DI as upfront therapy in HL https:\/\/clinicaltrials.gov\/show\/NCT03159897"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hon.2438","article-title":"Safety and efficacy analysis of elderly patients treated within the GATLA HL-05 clinical trial: PET adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma","volume":"35 Suppl 2","author":"Ciliberti","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/hon.2880","article-title":"MTV, TLG and Suv max as promising parameters to predict early response in patients with HL treated with ABVD. A retrospective sub-analysis of the GATLA LH-05 trial","volume":"39 Suppl 2","author":"Iorio","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0182|cit182","first-page":"5","article-title":"PET-CT adapted therapy after 3 cycles of ABVD to all stages of Hodgkin lymphoma. GATLA trial HL-05","volume":"101 Suppl 1","author":"Pavlovsky","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.15838","article-title":"PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial","volume":"185","author":"Pavlovsky","year":"2019","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/hon.2880","article-title":"PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA Lh-05 trial","volume":"39 Suppl 3","author":"Pavlovsky","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1097\/01.HS9.0000852292.38263.b8","article-title":"PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial","volume":"6 Suppl 3","author":"Pavlovsky","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0186|cit186","unstructured":"Very early FDG-PET\/CT-response adapted therapy for advanced Hodgkin lymphoma (H11) https:\/\/clinicaltrials.gov\/search?term=NCT01652261"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0187|cit187","first-page":"146","article-title":"Patient preferences - survey of Hodgkin lymphoma survivors on treatment-associated burden and side effects","volume":"101 Suppl 1","author":"Buerkle","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijrobp.2011.06.006","article-title":"Role of radiotherapy after assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma: final report of the GHSG HD15 trial","volume":"1","author":"Eich","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00066-011-1001-z","article-title":"Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin Lymphoma after completion of chemotherapy: final report of the GHSG HD15 trial","volume":"1","author":"Eich","year":"2011","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijrobp.2013.06.021","article-title":"Relapse analysis after radiation therapy of PET-positive residual tumors of patients with advanced stage Hodgkin lymphoma treated in the HD15 trial of the German Hodgkin Study Group (GHSG)","volume":"1","author":"Eich","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V116.21.2682.2682","article-title":"Secondary MDS\/AML in Hodgkin lymphoma patients treated within German Hodgkin Study Group (GHSG) clinical trials after introduction of the BEACOPP protocol","volume":"116","author":"Eichenauer","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/HS9.0000000000000005","article-title":"Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin Study Group","volume":"1","author":"Engert","year":"2017","journal-title":"HemaSphere"},{"issue":"9828","key":"10.1002\/14651858.CD010533.pub3-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736%2811%2961940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V118.21.589.589","article-title":"Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: the GHSG HD15 final results","volume":"118","author":"Engert","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V116.21.764.764","article-title":"Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: final report of the GHSG HD15 trial","volume":"116","author":"Engert","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0196|cit196","first-page":"96","article-title":"FDG-PET to guide radiotherapy in advanced-stage Hodgkin lymphoma patients with residual bulky disease after chemotherapy: results of the GHSG HD15 trial","volume":"4","author":"Engert","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0197|cit197","first-page":"455","article-title":"Comparing intensity of chemotherapy followed PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: final results of the GHSG HD15 trial","volume":"97 Suppl 1","author":"Engert","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010533.pub3-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00259-011-1908-8","article-title":"Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG HD15 trial","volume":"38","author":"Kobe","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","article-title":"Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma","volume":"112","author":"Kobe","year":"2008","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1311119","article-title":"Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG HD15 trial","volume":"184","author":"Kobe","year":"2012","journal-title":"Fortschritte Auf Dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3413\/Nukmed-0746-15-06","article-title":"Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma","volume":"54","author":"Kobe","year":"2015","journal-title":"Nuklearmedizin [Nuclear Medicine]"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010533.pub3-BIB0202|cit202","first-page":"3","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin study group","volume":"98","author":"Kriz","year":"2013","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010533.pub3-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00066-013-0339-9","article-title":"Analysis of relapses of irradiated patients within the HD15 trial of the German Hodgkin Study Group","volume":"189","author":"Kriz","year":"2013","journal-title":"Strahlentherapie und Onkologie"},{"issue":"11","key":"10.1002\/14651858.CD010533.pub3-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0205|cit205","unstructured":"Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma: comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12617000087358"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.HS9.0000890576.23258.1c","article-title":"Treatment related morbidity in patients with classical Hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by the German Hodgkin Study Group","volume":"6 Suppl 5","author":"Borchmann","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0207|cit207","first-page":"39","article-title":"HD21 Treatment optimization trial in the first-line treatment of advanced-stage Hodgkin lymphoma: comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD","volume":"10 Suppl 1","author":"Greil","year":"2017","journal-title":"Magazine of European Medical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0208|cit208","first-page":"S61","article-title":"GHSG-HD21: treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma: comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD","volume":"15","author":"Greil","year":"2022","journal-title":"Magazine of European Medical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0209|cit209","unstructured":"HD21 for advanced stages https:\/\/clinicaltrials.gov\/study\/NCT02661503"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0210|cit210","unstructured":"JCOG1305: Interim response adapted strategy for the advanced stage of Hodgkin Lymphoma https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs031180218"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Advances"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0213|cit213","unstructured":"PET-directed therapy with pembrolizumab and combination chemotherapy in treating patients with previously untreated classical Hodgkin lymphoma https:\/\/ClinicalTrials.gov\/show\/NCT03226249"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0214|cit214","unstructured":"Brentuximab vedotin and nivolumab in treating participants with early stage classic Hodgkin lymphoma https:\/\/clinicaltrials.gov\/show\/NCT03712202"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0215|cit215","unstructured":"PET adapted brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine in classic Hodgkin lymphoma https:\/\/classic.clinicaltrials.gov\/show\/NCT05922904"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0216|cit216","unstructured":"Brentuximab vedotin in early stage Hodgkin lymphoma https:\/\/clinicaltrials.gov\/show\/NCT04685616"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"RADAR: an international phase III, PET response adapted, randomised trial in progress, comparing ABVD +\/- LSRT with brentuximab vedotin +AVD +\/- LSRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6 Suppl 5","author":"Radford","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1120-1797(22)02417-6","article-title":"An example of prospective application of imaging biomarker: set-up of the first worldwide prospective phase III Onco-Hematological clinical trial using TMTV for patient stratification","volume":"104 Suppl 1","author":"Bergesio","year":"2022","journal-title":"Physica Medica"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/hon.3158","article-title":"Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography\/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma","volume":"441","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890652.56016.97","article-title":"Radiation-free therapy as the initial treatment of good-prognosis early non-bulky Hodgkin lymphoma, defined by a low metabolic tumor volume and a negative PET-2 - RAFTING trial","volume":"6 Suppl 5","author":"Gallamini","year":"2022","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0221|cit221","unstructured":"Radiation free chemotherapy for early Hodgkin lymphoma https:\/\/ClinicalTrials.gov\/show\/NCT04866654"},{"issue":"23","key":"10.1002\/14651858.CD010533.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.V126.23.1498.1498","article-title":"Feasibility of interim PET-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): sub-analysis of SWOG S0816 phase 2 trial","volume":"126","author":"Danilov","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10428194.2016.1201573","article-title":"Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial","volume":"58","author":"Danilov","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0224|cit224","unstructured":"S0816 Fludeoxyglucose F 18-PET\/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma https:\/\/ClinicalTrials.gov\/show\/NCT00822120"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hon.2057","article-title":"A phase II trial of response-adapted therapy of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816","volume":"1","author":"Press","year":"2013","journal-title":"Hematological Oncology"},{"issue":"17","key":"10.1002\/14651858.CD010533.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.2437_81","article-title":"The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US intergroup S0816 trial","volume":"35 Suppl 2","author":"Scott","year":"2017","journal-title":"Hematological Oncology"},{"issue":"15","key":"10.1002\/14651858.CD010533.pub3-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0229|cit229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012643.pub3","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","author":"Aldin","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010533.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2019.03.003","article-title":"Immunotherapy in Hodgkin lymphoma: the road ahead","volume":"40","author":"Ansell","year":"2019","journal-title":"Trends in Immunology"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"32","key":"10.1002\/14651858.CD010533.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group","volume":"29","author":"Borchmann","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000502425","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin study group (GHSG) and the Nordic Lymphoma Group (NLG)","volume":"42 Suppl 4","author":"Boll","year":"2019","journal-title":"Oncology Research and Treatment"},{"issue":"21","key":"10.1002\/14651858.CD010533.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0237|cit237","unstructured":"Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above https:\/\/clinicaltrials.gov\/study\/NCT05404945"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.04.002","article-title":"Established search filters may miss studies when identifying randomized controlled trials","volume":"112","author":"Cooper","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0239|cit239","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2022"},{"issue":"4","key":"10.1002\/14651858.CD010533.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"e18856","DOI":"10.1371\/journal.pone.0018856","article-title":"Lestaurtinib inhibition of the Jak\/STAT signalling pathway in Hodgkin lymphoma inhibits proliferation and induces apoptosis","volume":"6","author":"Diaz","year":"2011","journal-title":"PloS One"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010533.pub3-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD010533.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010533.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"9828","key":"10.1002\/14651858.CD010533.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"Guideline for the first-line management of classical Hodgkin lymphoma - a British Society for Haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD010533.pub3-BIB0246|cit246","first-page":"923","article-title":"Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features","volume":"22","author":"Fraga","year":"2007","journal-title":"Histology and Histopathology"},{"issue":"3","key":"10.1002\/14651858.CD010533.pub3-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"e0283694","DOI":"10.1371\/journal.pone.0283694","article-title":"Interobserver variability in interim PET assessment in Hodgkin lymphoma - reasons and solutions","volume":"18","author":"Georgi","year":"2023","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD010533.pub3-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Information and Libraries Journal"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD010533.pub3-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)- AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0250|cit250","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2017"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0251|cit251","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2023"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0253|cit253","first-page":"15","article-title":"First-line treatment of Hodgkin's lymphoma","volume":"4","author":"Klimm","year":"2005","journal-title":"Current Hematology Reports"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: NIVINIHO, a LYSA phase II study","volume":"138 Suppl 1","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0255|cit255","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2022"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0256|cit256","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Li","year":"2023"},{"issue":"11","key":"10.1002\/14651858.CD010533.pub3-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bjh.15789","article-title":"Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma","volume":"185","author":"Metzger","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD010533.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0261|cit261","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Page","year":"2024"},{"issue":"24","key":"10.1002\/14651858.CD010533.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2020.03.008","article-title":"2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma","volume":"132","author":"Picardi","year":"2020","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0264|cit264","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009411.pub2","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0265|cit265","unstructured":"Response adapted incorporation of tislelizumab into the front-line treatment of older patients with Hodgkin lymphoma (RATiFY) https:\/\/clinicaltrials.gov\/study\/NCT05627115"},{"issue":"12","key":"10.1002\/14651858.CD010533.pub3-BIB0266|cit266","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"18","key":"10.1002\/14651858.CD010533.pub3-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"Journal Of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0269|cit269","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Schunemann","year":"2024"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0270|cit270","unstructured":"Surveillance Research Program National Cancer Institute SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"issue":"8","key":"10.1002\/14651858.CD010533.pub3-BIB0271|cit271","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007941.pub3","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","author":"Skoetz","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010533.pub3-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3324\/haematol.2018.199844","article-title":"ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study","volume":"104","author":"Strati","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0273|cit273","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1002\/14651858.CD010533.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"e67\u201379","DOI":"10.1016\/S2352-3026(20)30357-4","article-title":"The role of PET in first-line treatment of Hodgkin lymphoma","volume":"8","author":"Trotman","year":"2021","journal-title":"Lancet Haematology"},{"issue":"17","key":"10.1002\/14651858.CD010533.pub3-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.3390\/ijms241713187","article-title":"Incorporating monoclonal antibodies into the first-line treatment of classical Hodgkin lymphoma","volume":"24","author":"Vassilakopoulos","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1002\/14651858.CD010533.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial","volume":"30","author":"Von Tresckow","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010533.pub3-BIB0278|cit278","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010533","article-title":"Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients","author":"Sickinger","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010533.pub3-BIB0279|cit279","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010533.pub2","article-title":"Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma","author":"Sickinger","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:44:06Z","timestamp":1786117446000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010533.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":279,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010533.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}